AbbVie
ABBV
$207.94
-2.10%
AbbVie Inc. is a global pharmaceutical company operating in the Drug Manufacturers - General industry, with a core business focused on immunology (Humira, Skyrizi, Rinvoq), oncology (Imbruvica, Venclexta), neuroscience, and aesthetics (Botox). The company is a market leader, particularly in immunology, and has established a distinct competitive identity through strategic acquisitions, such as Allergan in 2020 and Cerevel and ImmunoGen in 2024, to supplement its portfolio and pipeline. The current investor narrative is dominated by the successful transition from its legacy blockbuster Humira to newer immunology assets, with recent news highlighting promising early obesity drug data and strong clinical results for Skyrizi in Crohn's disease, which bolster its long-term growth prospects amidst new competitive threats like Johnson & Johnson's recently approved oral psoriasis drug.…
ABBV
AbbVie
$207.94
Related headlines
Investment Opinion: Should I buy ABBV Today?
Rating & Thesis: Hold. AbbVie presents a compelling long-term transition story at a reasonable valuation, but near-term earnings volatility and competitive threats warrant caution, aligning with the mixed but leaning bullish analyst sentiment. The core thesis is that the company is a GARP (Growth at a Reasonable Price) story temporarily obscured by acquisition-related noise.
Supporting Evidence: The forward P/E of 12.93x is attractive relative to the sector. Revenue growth is solid at 10.04% YoY, driven by Skyrizi and Rinvoq. The company generates immense free cash flow ($18.70B TTM) to fund its 2.85% dividend. Analyst consensus estimates project robust forward EPS of $20.04, implying significant earnings growth from the depressed trailing base.
Risks & Conditions: The two biggest risks are the recurrence of large, non-operating expenses that devastate quarterly profits and successful market penetration by J&J's new competing drug. This Hold rating would upgrade to a Buy if quarterly net income stabilizes consistently above $1.5 billion, signaling the end of earnings volatility, or if the forward P/E compresses further toward 11x. It would downgrade to Sell if revenue growth decelerates below 5% or if the dividend payout ratio rises unsustainably above 3.0. The stock is currently fairly valued relative to its near-term prospects but undervalued if its long-term earnings power materializes as projected.
Sign up to view all
ABBV 12-Month Price Forecast
The outlook for AbbVie is bifurcated between its strong underlying business momentum and its messy, acquisition-distorted financials. The base case of gradual normalization is most likely, but the path will be uneven. The stock's low beta and dividend offer downside protection, while the cheap forward multiple provides upside if earnings stabilize. The stance is neutral due to the high degree of uncertainty around quarterly profitability. An upgrade to bullish would require two consecutive quarters of clean, predictable earnings that align with the forward EPS estimate of $20.04. A downgrade to bearish would be triggered by a guidance cut or a failure of the new immunology drugs to maintain their growth trajectory.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on AbbVie's 12-month outlook, with a consensus price target around $270.32 and implied upside of +30.0% versus the current price.
Average Target
$270.32
11 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
11
covering this stock
Price Range
$166 - $270
Analyst target range
AbbVie is covered by 11 analysts, with recent institutional ratings showing a mix of Buy/Overweight and Neutral stances, including reaffirmations from Morgan Stanley and Piper Sandler, a downgrade from Wolfe Research, and an upgrade from HSBC. The consensus sentiment leans bullish, supported by an average estimated EPS of $20.04 and average estimated revenue of $83.32 billion for the coming year, implying confidence in the company's growth trajectory. The target price range is not explicitly provided in the data, but the pattern of analyst actions and earnings estimates suggests moderate conviction, though the recent price decline may prompt revisions. A wide target spread would signal high uncertainty regarding the success of the newer drug launches and competitive landscape, while a tight spread would indicate stronger agreement on the company's ability to execute its post-Humira transition.
Bulls vs Bears: ABBV Investment Factors
The investment debate for AbbVie centers on a clash between its solid fundamental transition and its alarming financial volatility. The bull case is anchored by a successful revenue shift to new immunology drugs, a cheap forward valuation, and a strong dividend, while the bear case highlights severe quarterly earnings instability, a leveraged balance sheet, and emerging competition. Currently, the bearish evidence from recent earnings volatility and technical breakdown carries more immediate weight, overshadowing the promising long-term narrative. The single most important tension is whether the extreme quarterly profit swings (e.g., Q4 net income of $1.82B vs. Q3's $186M) are temporary acquisition-related integration costs or a sign of deeper structural profitability issues. The resolution of this earnings normalization will be the primary determinant of the stock's direction.
Bullish
- Strong Revenue Growth & Immunology Transition: Q4 2025 revenue grew 10.04% YoY to $16.62B, driven by Skyrizi ($5.01B) and Rinvoq ($2.37B), successfully offsetting Humira's decline to $1.25B. This demonstrates the core immunology franchise is executing the post-Humira transition effectively.
- Attractive Forward Valuation: The forward P/E of 12.93x sits at a discount to the broader pharmaceutical industry and at the lower end of AbbVie's own historical range. This suggests the market is pricing in conservative earnings expectations, offering a potential value opportunity.
- Robust Cash Generation & Dividend: Trailing twelve-month free cash flow of $18.70 billion supports a healthy dividend yield of 2.85%. The company's consistent dividend declarations underscore its financial strength and commitment to shareholder returns.
- Pipeline Catalysts in Key Markets: Recent positive developments include strong Phase 3 results for Skyrizi in Crohn's disease (55% remission) and early obesity drug data showing up to 10% weight loss. These bolster long-term growth prospects in high-value therapeutic areas.
Bearish
- Severe Earnings Volatility & Margin Pressure: Net income plummeted from $1.82B in Q4 2025 to just $186M in Q3 2025, with the net margin compressing to 1.18%. This extreme quarterly volatility, driven by large 'other expenses,' creates significant uncertainty around sustainable profitability.
- Deteriorating Balance Sheet & Liquidity: The debt-to-equity ratio is a negative -21.12 due to negative shareholder equity from acquisition-related goodwill. Furthermore, the current ratio of 0.67 indicates potential near-term liquidity pressure despite strong cash flow.
- Intensifying Competitive Threats: The recent FDA approval of Johnson & Johnson's oral psoriasis drug Icotyde introduces new, convenient competition for AbbVie's blockbuster Skyrizi. This threatens pricing power and market share in the critical immunology segment.
- Recent Technical Breakdown & Underperformance: The stock is down 8.67% over the past month and has underperformed the SPY by 9.13% in that period, breaking down from a multi-month trading range. This price action reflects waning investor confidence and negative momentum.
ABBV Technical Analysis
The prevailing price trend for AbbVie has been a downtrend over the observed 180-day period, culminating in a current price of $207.94, which represents a 1-year price change of +19.37%. The stock is trading at approximately 51.6% of its 52-week range ($168.54 to $244.81), positioning it near the midpoint, which suggests a lack of clear directional momentum and reflects investor uncertainty following a significant pullback from recent highs. Recent momentum has been decisively negative, with the stock down 8.67% over the past month and 5.52% over the past three months, sharply diverging from the positive 1-year trend and signaling a potential breakdown or consolidation phase. This short-term weakness is further evidenced by a relative strength of -9.13 against the SPY over one month, indicating significant underperformance. Key technical support is at the 52-week low of $168.54, while resistance sits at the 52-week high of $244.81; a sustained break below the recent lows near $205 could signal a deeper correction, whereas a recovery above $235 would suggest trend reversal. The stock's beta of 0.364 indicates it is significantly less volatile than the broader market, which historically provides defensive characteristics but may limit upside participation during strong market rallies.
Beta
0.36
0.36x market volatility
Max Drawdown
-21.5%
Largest decline past year
52-Week Range
$169-$245
Price range past year
Annual Return
+19.4%
Cumulative gain past year
| Period | ABBV Return | S&P 500 |
|---|---|---|
| 1m | -8.7% | +2.6% |
| 3m | -5.5% | -2.3% |
| 6m | -9.8% | +2.6% |
| 1y | +19.4% | +27.3% |
| ytd | -9.3% | -0.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ABBV Fundamental Analysis
AbbVie's revenue trajectory shows solid growth, with Q4 2025 revenue of $16.62 billion representing a 10.04% year-over-year increase, a significant acceleration from the prior quarter's $15.78 billion. The multi-quarter trend reveals revenue has grown sequentially from $13.34 billion in Q1 2025, driven primarily by the blockbuster immunology franchise, where Skyrizi contributed $5.01 billion and Rinvoq $2.37 billion in the latest period, successfully offsetting the decline of Humira ($1.25 billion). The company is profitable, reporting Q4 2025 net income of $1.82 billion and a robust gross margin of 84.02%, though profitability has been volatile quarter-to-quarter, with net income margins compressing from 10.93% in Q4 2025 to just 1.18% in Q3 2025 due to significant other expenses. The full-year trend shows a recovery from a net loss in Q4 2024, indicating the company is navigating past acquisition-related integration costs and moving towards more stable earnings. AbbVie's balance sheet and cash flow position is strong, with trailing twelve-month free cash flow of $18.70 billion, supporting a dividend yield of 2.85% and a payout ratio of 2.76. However, the debt-to-equity ratio is reported at -21.12, an artifact of negative shareholder equity due to large intangible assets and goodwill from acquisitions, while the current ratio of 0.67 indicates moderate liquidity pressure, though the substantial cash generation capacity mitigates near-term financial risk.
Quarterly Revenue
$16.6B
2025-12
Revenue YoY Growth
+0.10%
YoY Comparison
Gross Margin
+0.84%
Latest Quarter
Free Cash Flow
$18.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ABBV Overvalued?
Given AbbVie's positive net income of $1.82 billion in the latest quarter, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE is elevated at 96.82x, while the forward PE is substantially lower at 12.93x, indicating the market expects a significant normalization and growth in earnings over the next year, likely as one-time costs subside. Compared to sector averages, AbbVie's forward PE of 12.93x trades at a discount to the broader pharmaceutical industry, which often trades in the mid-teens, suggesting the market may be undervaluing its earnings power or pricing in pipeline risks. The discount is potentially justified by the company's high debt load and integration challenges from recent acquisitions, offsetting its strong immunology franchise. Historically, the stock's own PE ratio has fluctuated wildly, from as high as 551.46x in Q3 2025 to as low as 14.80x in late 2021; the current forward multiple near 13x sits at the lower end of its historical range, suggesting the stock is pricing in conservative expectations and may represent a value opportunity if earnings stabilize as projected.
PE
96.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -3572x~551x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
16.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: AbbVie's primary financial risk is extreme earnings volatility, as evidenced by net income plunging from $1.82 billion in Q4 2025 to $186 million in Q3 2025. This is compounded by a leveraged balance sheet with negative shareholder equity (-21.12 D/E) and a weak current ratio of 0.67, indicating liquidity strain. While massive free cash flow ($18.70B TTM) mitigates near-term solvency risk, the company remains dependent on the flawless execution of its immunology transition to stabilize margins, as Humira revenue continues its decline to $1.25B last quarter.
Market & Competitive Risks: The stock faces valuation compression risk if its forward P/E of 12.93x, already a sector discount, fails to expand due to persistent earnings uncertainty. Externally, the recent FDA approval of Johnson & Johnson's oral psoriasis drug represents a direct competitive threat to Skyrizi's market leadership. Furthermore, the stock's low beta of 0.364, while defensive, may cause it to lag during strong market rallies, as seen in its -10.15% relative underperformance vs. the SPY over the past year.
Worst-Case Scenario: The worst-case scenario involves a combination of faster-than-expected market share loss for Skyrizi/Rinvoq to new oral competitors, a failure of pipeline catalysts like the obesity drug, and a failure to control the volatile 'other expenses' that have crushed quarterly profits. This could lead to consecutive earnings misses, dividend growth stagnation, and multiple compression. Realistic downside could see the stock re-test its 52-week low of $168.54, representing a potential loss of approximately -19% from the current price of $207.94.
FAQ
The key risks are, in order of severity: 1) Financial Risk: Extreme quarterly earnings volatility and a leveraged balance sheet with negative equity (-21.12 D/E). 2) Competitive Risk: New market entrants like J&J's oral psoriasis drug threatening the growth of Skyrizi/Rinvoq. 3) Execution Risk: Failure to successfully integrate the Cerevel and ImmunoGen acquisitions or realize their pipeline value. 4) Macro/Rating Risk: The stock's low beta (0.364) may cause it to underperform in strong bull markets, as evidenced by its -10%+ relative underperformance vs. the SPY over the past year.
The 12-month forecast presents three scenarios. The Base Case (55% probability) sees the stock trading between $225 and $240 as earnings gradually normalize, aligning with analyst EPS estimates of $20.04. The Bull Case (30% probability) targets $244 to $260 on sustained high profitability and successful pipeline updates. The Bear Case (15% probability) warns of a drop toward the 52-week low of $168 if earnings volatility persists and competition intensifies. The Base Case is most likely, contingent on AbbVie demonstrating more consistent quarterly profits.
ABBV appears fairly valued to slightly undervalued based on forward earnings potential. The trailing P/E of 96.82x is misleading due to recent one-time costs. The relevant forward P/E of 12.93x trades at a discount to the broader pharmaceutical industry, suggesting the market is undervaluing its normalized earnings power. Compared to its own history, a forward multiple near 13x is at the lower end of its range. The valuation implies the market expects moderate growth with continued integration challenges, pricing in little credit for pipeline success.
ABBV is a good buy for a specific investor profile: those seeking a high dividend yield (2.85%) from a pharmaceutical leader, who have a long-term horizon and can stomach significant quarterly earnings volatility. The forward P/E of 12.93x offers a margin of safety, and analyst consensus points to substantial EPS growth. However, it is not a good buy for short-term traders or those sensitive to earnings surprises, given the recent profit swings from $1.82B to $0.19B between quarters. The biggest downside risk is a failure to stabilize profitability.
ABBV is unequivocally suitable for long-term investment, with a suggested minimum holding period of 3-5 years. Its low beta (0.364) and high dividend are hallmarks of a long-term holding, and the investment thesis revolves around the multi-year transition of its drug portfolio. The stock is poorly suited for short-term trading due to its low volatility and susceptibility to earnings-related gaps, as seen in the recent 8.67% monthly decline. Long-term investors can collect the dividend while awaiting the resolution of near-term financial noise and pipeline maturation.